

## Special Issue

# HIV Pathogenesis, Vaccine and Eradication Strategies

### Message from the Guest Editor

Human Immunodeficiency Virus (HIV) is still a very big problem for humanity. Fortunately, current anti-HIV drug regimens are highly effective in controlling HIV transmission and replication. Notably, it has been well established that current anti-HIV therapy would not be able to eradicate or cure HIV. Numerous strategies have been applied unsuccessfully to flush out the latent HIV reservoirs, the main hurdle in HIV eradication. However, due to mutadaptability of HIV, both preventive and therapeutic vaccines have been proved ineffective. In addition, several other prophylactic approaches, including microbicides, are struggling to make impact. We are interested in a broader area of research, focusing primarily on the mechanisms of HIV pathogenesis, life cycle, latency and therapeutics. In addition, we are calling manuscripts dealing with vaccine trials (pre-clinical and clinical) and strategies to develop more effective HIV vaccine. We are looking forward to have a combination of manuscripts that deals with different vital aspects of HIV, which could be exploited to develop more effective anti-HIV therapy.

### Guest Editor

Dr. Mudit Tyagi

Thomas Jefferson University, Philadelphia, USA

### Deadline for manuscript submissions

closed (28 February 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/41610](https://mdpi.com/si/41610)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).